Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication
This article was originally published in PharmAsia News
Executive Summary
Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia
You may also be interested in...
Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin
TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai
Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin
TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai
Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook
TOKYO - Having no large extra charges for acquisitions like its Japanese competitors, Astellas Pharma predicted Nov. 5 revenues and earnings for fiscal 2008 would be slightly better than its earlier forecast but the yen's appreciation and slow new drug launches would nudge the performance modestly lower than in the preceding business year